Kodiak Sciences (KOD) Return on Capital Employed (2018 - 2026)
Kodiak Sciences (KOD) reported Return on Capital Employed of 84.2% for Q1 2026, down 1429.0% on a YoY basis from 6.34% in Q1 2025, and up 14.04% quarter-over-quarter from 97.96% in Q4 2025.
Kodiak Sciences (KOD) Return on Capital Employed (2018 - 2026) Analysis & Trends
Kodiak Sciences has reported Return on Capital Employed for 9 years, with the latest figure at 84.2% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 1429.0% year-over-year to 84.2%; the trailing twelve-month figure through Mar 2026 stood at 84.2% (down 1429.0% YoY), and the FY2025 full-year result was 78.65%, down 2972.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 84.2%, up from 97.96% in the prior quarter.
- The five-year high for Return on Capital Employed was 38.99% in Q1 2022, with the low at 114.44% in Q3 2025.
- Historically, Return on Capital Employed has averaged 64.43% across 5 years, with a median of 57.56% in 2024.
- Annual changes were most pronounced in 2024 — Return on Capital Employed soared 450 bps — and 2025, when it sank 5824 bps.
- Kodiak Sciences' Return on Capital Employed stood at 53.11% in 2022, then slipped by 11 bps to 58.78% in 2023, then increased by 3 bps to 56.87% in 2024, then slumped by 72 bps to 97.96% in 2025, then gained by 14 bps to 84.2% in 2026.
- The last three Return on Capital Employed figures came in at 84.2% (Q1 2026), 97.96% (Q4 2025), and 114.44% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -107.40% |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -50.43% |
| 10 | Kodiak Sciences | 1.95 Bn | 1.95 Bn | - | -84.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -84.20% |
| Dec 31, 2025 | -97.96% |
| Sep 30, 2025 | -114.44% |
| Jun 30, 2025 | -84.20% |
| Mar 31, 2025 | -69.92% |
| Dec 31, 2024 | -56.87% |
| Sep 30, 2024 | -56.20% |
| Jun 30, 2024 | -53.38% |
| Mar 31, 2024 | -57.56% |
| Dec 31, 2023 | -58.78% |
| Sep 30, 2023 | -57.85% |
| Jun 30, 2023 | -57.88% |
| Mar 31, 2023 | -54.78% |
| Dec 31, 2022 | -53.11% |
| Sep 30, 2022 | -52.43% |
| Jun 30, 2022 | -46.69% |
| Mar 31, 2022 | -38.99% |
| Dec 31, 2021 | -30.82% |
| Sep 30, 2021 | -23.91% |
| Jun 30, 2021 | -19.50% |